Alkane Energy
BUYClean-tech counter Alkane Energy, the owner and operator of ‘gas-to-power’ plants, is growing fast and has honed its strategic focus.
Alkane gains onshore gas licences and exploits its gas reserves by selling directly to customers or, more significantly, generating electricity which it then sells via the electricity distribution network.
In 2008, the group, whose gas source, coal mine methane, is extracted from abandoned collieries, grew revenue 22% to £5.2m and adjusted PBT on ongoing business by 59% to more than £1.4m.
CEO Neil O’Brien flagged up a strong year of production from Alkane’s UK power assets, with electricity generated increasing 13% to a record 90,111 MWh and the average selling price advancing by 15% – additionally, 3.7 million therms of gas were sold direct to customers at higher average prices.
With a large spread of projects, O’Brien’s medium-term target is to grow power generation capacity from 20 MW to 50 MW, with select acquisitions in the gas-to-power sector also to be considered.
He says the post year-end sale of a 38% stake in German joint venture Pro2, which makes equipment for the processing and utilisation of methane, to a German power concern for €3.6m in cash (total receipts will be €7.56m), has simplified the story for investors and left Alkane ungeared.
Based on current trading, likely growth in capacity and higher contracted electricity prices in 2009, good growth is now on the cards at this real business with cash-generating assets. Occupying a stable industry (demand for electricity doesn’t falter during recession) and offering resilient growth, the shares are a buy.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £15.8m
Share price: 17p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
